Industry Growth Insights published a new data on “Metabotropic Glutamate Receptor 2 Market”. The research report is titled “Metabotropic Glutamate Receptor 2 Market research by Types (LY-2607540, BMT-133218, DT-2442, JNJ-40411813, Others), By Applications (Anxiety Disorders, Depression, Schizophrenia, Chronic Pain, Others), By Players/Companies Addex Therapeutics Ltd, Bristol-Myers Squibb Company, Denovo Biopharma LLC, Domain Therapeutics SA, Eli Lilly and Company, Johnson & Johnson, Merck & Co Inc, ...”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Metabotropic Glutamate Receptor 2 Market Research Report
By Type
LY-2607540, BMT-133218, DT-2442, JNJ-40411813, Others
By Application
Anxiety Disorders, Depression, Schizophrenia, Chronic Pain, Others
By Companies
Addex Therapeutics Ltd, Bristol-Myers Squibb Company, Denovo Biopharma LLC, Domain Therapeutics SA, Eli Lilly and Company, Johnson & Johnson, Merck & Co Inc, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Metabotropic Glutamate Receptor 2 Market Report Segments:
The global Metabotropic Glutamate Receptor 2 market is segmented on the basis of:
Types
LY-2607540, BMT-133218, DT-2442, JNJ-40411813, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anxiety Disorders, Depression, Schizophrenia, Chronic Pain, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Addex Therapeutics Ltd
- Bristol-Myers Squibb Company
- Denovo Biopharma LLC
- Domain Therapeutics SA
- Eli Lilly and Company
- Johnson & Johnson
- Merck & Co Inc
- ...
Highlights of The Metabotropic Glutamate Receptor 2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- LY-2607540
- BMT-133218
- DT-2442
- JNJ-40411813
- Others
- By Application:
- Anxiety Disorders
- Depression
- Schizophrenia
- Chronic Pain
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metabotropic Glutamate Receptor 2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metabotropic glutamate receptor 2 is a type of glutamate receptor that is responsible for mediating the effects of glutamate in the brain. This receptor is particularly important in controlling nerve cell activity, and can be activated by various substances such as neurotransmitters or stressors.
Some of the major companies in the metabotropic glutamate receptor 2 market are Addex Therapeutics Ltd, Bristol-Myers Squibb Company, Denovo Biopharma LLC, Domain Therapeutics SA, Eli Lilly and Company, Johnson & Johnson, Merck & Co Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Metabotropic Glutamate Receptor 2 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Metabotropic Glutamate Receptor 2 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Metabotropic Glutamate Receptor 2 Market - Supply Chain
4.5. Global Metabotropic Glutamate Receptor 2 Market Forecast
4.5.1. Metabotropic Glutamate Receptor 2 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Metabotropic Glutamate Receptor 2 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Metabotropic Glutamate Receptor 2 Market Absolute $ Opportunity
5. Global Metabotropic Glutamate Receptor 2 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Type
5.3.1. LY-2607540
5.3.2. BMT-133218
5.3.3. DT-2442
5.3.4. JNJ-40411813
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Metabotropic Glutamate Receptor 2 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Application
6.3.1. Anxiety Disorders
6.3.2. Depression
6.3.3. Schizophrenia
6.3.4. Chronic Pain
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Metabotropic Glutamate Receptor 2 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Metabotropic Glutamate Receptor 2 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Metabotropic Glutamate Receptor 2 Demand Share Forecast, 2019-2029
9. North America Metabotropic Glutamate Receptor 2 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Application
9.4.1. Anxiety Disorders
9.4.2. Depression
9.4.3. Schizophrenia
9.4.4. Chronic Pain
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Type
9.7.1. LY-2607540
9.7.2. BMT-133218
9.7.3. DT-2442
9.7.4. JNJ-40411813
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Metabotropic Glutamate Receptor 2 Demand Share Forecast, 2019-2029
10. Latin America Metabotropic Glutamate Receptor 2 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Application
10.4.1. Anxiety Disorders
10.4.2. Depression
10.4.3. Schizophrenia
10.4.4. Chronic Pain
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Type
10.7.1. LY-2607540
10.7.2. BMT-133218
10.7.3. DT-2442
10.7.4. JNJ-40411813
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Metabotropic Glutamate Receptor 2 Demand Share Forecast, 2019-2029
11. Europe Metabotropic Glutamate Receptor 2 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Application
11.4.1. Anxiety Disorders
11.4.2. Depression
11.4.3. Schizophrenia
11.4.4. Chronic Pain
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Type
11.7.1. LY-2607540
1.7.2. BMT-133218
11.7.3. DT-2442
11.7.4. JNJ-40411813
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Metabotropic Glutamate Receptor 2 Demand Share, 2019-2029
12. Asia Pacific Metabotropic Glutamate Receptor 2 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Application
12.4.1. Anxiety Disorders
12.4.2. Depression
12.4.3. Schizophrenia
12.4.4. Chronic Pain
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Type
12.7.1. LY-2607540
12.7.2. BMT-133218
12.7.3. DT-2442
12.7.4. JNJ-40411813
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Metabotropic Glutamate Receptor 2 Demand Share, 2019-2029
13. Middle East & Africa Metabotropic Glutamate Receptor 2 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Application
13.4.1. Anxiety Disorders
13.4.2. Depression
13.4.3. Schizophrenia
13.4.4. Chronic Pain
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Metabotropic Glutamate Receptor 2 Market Size and Volume Forecast by Type
13.7.1. LY-2607540
13.7.2. BMT-133218
13.7.3. DT-2442
13.7.4. JNJ-40411813
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Metabotropic Glutamate Receptor 2 Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Metabotropic Glutamate Receptor 2 Market: Market Share Analysis
14.2. Metabotropic Glutamate Receptor 2 Distributors and Customers
14.3. Metabotropic Glutamate Receptor 2 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Addex Therapeutics Ltd
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bristol-Myers Squibb Company
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Denovo Biopharma LLC
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Domain Therapeutics SA
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eli Lilly and Company
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck & Co Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. ...
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
